IBRUTINIB

Pre-LaunchSM

ibrutinib

ANDAORALCAPSULE
Lifecycle
Pre-Launch
Clinical Trials
20

Clinical Trials (5)

NCT07456891Phase 3Not Yet Recruiting

Remibrutinib Open Label Roll-over Post-trial Access Protocol

Started Apr 2026
212 enrolled
Indication of the Parent Protocol
NCT07222956Phase 2Not Yet Recruiting

A Study of Remibrutinib Using MR Imaging in Relapsing or Progressive MS

Started Apr 2026
20 enrolled
Multiple Sclerosis (MS) - Relapsing-remittingMultiple Sclerosis (MS) Secondary ProgressiveMultiple Sclerosis (MS) Primary Progressive
NCT07358364N/ARecruiting

Remibrutinib in Real-world Clinical Practice

Started Feb 2026
3,280 enrolled
Chronic Spontaneous Urticaria
NCT07358780N/ARecruiting

Remibrutinib in Real-world Clinical Practice - a US Sub-study

Started Feb 2026
505 enrolled
Chronic Spontaneous Urticaria
NCT07408219N/ARecruiting

A Real-world Study of Remibrutinib in Chronic Spontaneous Urticaria Patients

Started Jan 2026
350 enrolled
Chronic Spontaneous Urticaria